Cargando…

Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab

Background: Bevacizumab, a vascular endothelial growth factor (VEGF) monoclonal antibody commonly used for the treatment of various cancers, is often associated with adverse cardiovascular effects such as hypertension, cardiac and cerebral ischemia, thrombosis, and bleeding events. Factors associate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ngo, Doan T. M., Williams, Trent, Horder, Sophie, Kritharides, Leonard, Vardy, Janette, Mandaliya, Hiren, Nordman, Ina I. C., Lynam, James, Bonaventura, Tony, Sverdlov, Aaron L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465018/ https://www.ncbi.nlm.nih.gov/pubmed/32824667 http://dx.doi.org/10.3390/jcm9082664

Ejemplares similares

Metastatic Eccrine Porocarcinoma: A Rare Case of Successful Treatment
por: Mandaliya, Hiren, et al.
Publicado: (2016)

Examining real world quality of care for Australia’s First Peoples presenting with chest pain
por: Williams, Trent D., et al.
Publicado: (2023)

Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE)
por: Chen, Dongqing, et al.
Publicado: (2023)

Successful immune checkpoint inhibitor rechallenge after immune-related pericarditis: Clinical case series
por: Chye, Adrian M., et al.
Publicado: (2022)

Phase I trial of hypofractionated chemoradiotherapy in the palliative management of esophageal and gastro-esophageal cancer
por: Sridharan, Swetha, et al.
Publicado: (2022)

Cardiovascular outcomes of cancer patients in rural Australia
por: Williams, Trent D., et al.
Publicado: (2023)

Early access to a cardio-oncology clinic in an Australian context: a qualitative exploration of patient experiences
por: White, Jennifer, et al.
Publicado: (2022)

Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies
por: Lee, Shu-Ping, et al.
Publicado: (2019)

Nexus of Cancer and Cardiovascular Disease for Australia’s First Peoples
por: Diaz, Abbey, et al.
Publicado: (2020)

Inflammatory Markers and Outcomes in Cardiovascular Disease
por: Kritharides, Leonard
Publicado: (2009)

An Updated Meta-Analysis of Fatal Adverse Events Caused by Bevacizumab Therapy in Cancer Patients
por: Huang, Hongxin, et al.
Publicado: (2014)

Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab
por: Hsu, Chiun, et al.
Publicado: (2021)

Interplay between Oxidative Stress and Inflammation in Cardiometabolic Syndrome
por: Sverdlov, Aaron L., et al.
Publicado: (2016)

Incidentally identified coronary artery calcium on non-contrast CT scan of the chest predicts major adverse cardiac events among hospital inpatients
por: Yu, Christopher, et al.
Publicado: (2021)

Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta‐Analysis of More Than 20 000 Patients
por: Totzeck, Matthias, et al.
Publicado: (2017)

A Survey of Medical Oncology Training in Australian Medical Schools: Pilot Study
por: George, Mathew, et al.
Publicado: (2017)

Comparison of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Injection: Ranibizumab versus Bevacizumab
por: Hwang, Duck Jin, et al.
Publicado: (2012)

Erratum to “Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab”
Publicado: (2021)

Choroid Melanoma Metastasis to Spine: A Rare Case Report
por: Mandaliya, Hiren, et al.
Publicado: (2016)

“POLAR-izing” Findings From Trials of Neuroprotection for Oxaliplatin Neuropathy
por: Teng, Christina, et al.
Publicado: (2022)

Bevacizumab-Induced Reversible Thrombocytopenia in a Patient with Adenocarcinoma of Colon: Rare Adverse Effect of Bevacizumab
por: Kumar, Jeevan, et al.
Publicado: (2012)

A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events
por: Hayashi, Hidemi, et al.
Publicado: (2022)

Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
por: Fukushima, Taito, et al.
Publicado: (2023)

Overexpression of Mitochondrial Catalase within Adipose Tissue Does Not Confer Systemic Metabolic Protection against Diet-Induced Obesity
por: Croft, Amanda J., et al.
Publicado: (2023)

A Rare Case of Paclitaxel and/or Trastuzumab Induced Acute Hepatic Necrosis
por: Mandaliya, Hiren, et al.
Publicado: (2015)

Cardiovascular and Logistic Issues Associated With COVID-19 Pandemic
por: Robert Denniss, A., et al.
Publicado: (2020)

Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab
por: GHERMAN, ALEXANDRA, et al.
Publicado: (2017)

Aging of the Nitric Oxide System: Are We as Old as Our NO?
por: Sverdlov, Aaron L., et al.
Publicado: (2014)

Systemic Adverse Events after Intravitreal Bevacizumab versus Ranibizumab for Age-Related Macular Degeneration: A Meta-Analysis
por: Wang, Wei, et al.
Publicado: (2014)

Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Tada, Toshifumi, et al.
Publicado: (2022)

Prostate Cancer: Cases of Rare Presentation and Rare Metastasis
por: Mandaliya, Hiren, et al.
Publicado: (2015)

Control of modifiable risk factors and major adverse cardiovascular events in people with peripheral artery disease and diabetes
por: Golledge, Jonathan, et al.
Publicado: (2021)

The Role of Pathological Aging in Cardiac and Pulmonary Fibrosis
por: Murtha, Lucy A., et al.
Publicado: (2019)

Bevacizumab for the treatment of post-stereotactic radiosurgery adverse radiation effect
por: Fanous, Andrew A., et al.
Publicado: (2016)

Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis
por: Li, Xiaoqing, et al.
Publicado: (2015)

Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
por: Shimose, Shigeo, et al.
Publicado: (2022)

Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
por: Xun, Xueqiong, et al.
Publicado: (2023)

Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019)

Treatment of Sciatica Following Uterine Cancer with Acupuncture: A Case Report
por: Xiao, Henry, et al.
Publicado: (2018)

Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system
por: Bai, Shuai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f3rbp4u4m3pbd2h8do8clokrp4